sacituzumab
Gilead
[' sg ', 'mbc', 'bcsm', 'tropics-02']
tropics-02 trial: sg continues to show benefit vs tpc with additional follow up in hr+/her2- mbc 35% in risk of progression
21% in risk of death benefit seen regardless of trop2 expression and her2 status(low vs null) #bcsm #asco23 
Breast Medical Oncologist @UNC_Lineberger Prior @JCO_ASCO editorial fellow. Views are my own.